Involvement of the Akt/mTOR pathway on EGF-induced cell transformation

被引:37
作者
Nomura, M
He, ZW
Koyama, I
Ma, WY
Miyamoto, K
Dong, ZG
机构
[1] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA
[2] Kanazawa Univ, Sch Med, Dept Hosp Pharm, Kanazawa, Ishikawa 920, Japan
关键词
mTOR; rapamycin; Akt; p70; S6K; EGF; cell transformation;
D O I
10.1002/mc.10140
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Our previous study demonstrated that phosphatidylinositol 3-kinase (PI3K) is necessary for epidermal growth factor (EGF)-induced cell transformation in mouse epidermal JB6 cells. Akt and the mammalian target of rapamycin (mTOR) are regarded as PI3K downstream effectors. Therefore, in this study, we investigated the role of Akt and mTOR on EGF-induced cell transformation in JB6 cells using rapamycin, a specific mTOR inhibitor, and cells expressing dominant negative mutants of Akt1 (DNM-Akt1). We found that the treatment of cells with rapamycin inhibited EGF-induced cell transformation but only slightly inhibited JB6 cell proliferation at 72 h. Although LY294002, a PI3K inhibitor, attenuated EGF-induced activator protein 1 (AP-1) activation, treatment with rapamycin did not affect AP-1 activity. Treatment with rapamycin inhibited EGF-induced phosphorylation and activation of ribosomal p70 S6 protein kinase (p70 S6K), an mTOR downstream target, but had no effect on phosphorylation and activation of Akt. Rapamycin also had no effect on EGF-induced phosphorylation of extracellular signal-regulated protein kinases (ERKs). We showed that introduction of DNM-Akt1 into JB6 mouse epidermal Cl 41 (JB6 Cl 41) cells inhibits EGF-induced cell transformation without blocking cell proliferation. The expression of DNM-Akt1 also suppressed EGF-induced p70 S6K activation as well as At activation. These results indicated an involvement of the Akt/mTOR pathway in EGF-induced cell transformation in JB6 cells. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:25 / 32
页数:8
相关论文
共 51 条
[41]  
2-H
[42]   An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice [J].
Podsypanina, K ;
Lee, RT ;
Politis, C ;
Hennessy, I ;
Crane, A ;
Puc, J ;
Neshat, M ;
Wang, H ;
Yang, L ;
Gibbons, J ;
Frost, P ;
Dreisbach, V ;
Blenis, J ;
Gaciong, Z ;
Fisher, P ;
Sawyers, C ;
Hedrick-Ellenson, L ;
Parsons, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (18) :10320-10325
[43]   ISOLATION OF A PROTEIN TARGET OF THE FKBP12-RAPAMYCIN COMPLEX IN MAMMALIAN-CELLS [J].
SABERS, CJ ;
MARTIN, MM ;
BRUNN, GJ ;
WILLIAMS, JM ;
DUMONT, FJ ;
WIEDERRECHT, G ;
ABRAHAM, RT .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (02) :815-822
[44]  
Sekulic A, 2000, CANCER RES, V60, P3504
[45]   PIK3CA is implicated as an oncogene in ovarian cancer [J].
Shayesteh, L ;
Lu, YL ;
Kuo, WL ;
Baldocchi, R ;
Godfrey, T ;
Collins, C ;
Pinkel, D ;
Powell, B ;
Mills, GB ;
Gray, JW .
NATURE GENETICS, 1999, 21 (01) :99-102
[46]   The mRNA 5′ cap-binding protein eIF4E and control of cell growth [J].
Sonenberg, N ;
Gingras, AC .
CURRENT OPINION IN CELL BIOLOGY, 1998, 10 (02) :268-275
[47]   Modulation of cellular apoptotic potential: contributions to oncogenesis [J].
Stambolic, V ;
Mak, TW ;
Woodgett, JR .
ONCOGENE, 1999, 18 (45) :6094-6103
[48]   Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway [J].
West, MJ ;
Stoneley, M ;
Willis, AE .
ONCOGENE, 1998, 17 (06) :769-780
[49]  
Wiederrecht G J, 1995, Prog Cell Cycle Res, V1, P53
[50]   Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR [J].
Yokogami, K ;
Wakisaka, S ;
Avruch, J ;
Reeves, SA .
CURRENT BIOLOGY, 2000, 10 (01) :47-50